Interferon-alpha-induced focal segmental glomerulosclerosis in chronic myelogenous leukemia: A case report and review of the literature

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 26, Issue 3, 2003, Pages 262-264

  Bremer, CelesteAnn T ^a,d   Lastrapes, Ashton ^c   Alper Jr , Arnold B ^b   Mudad, Raja ^a  

^a TULANE UNIVERSITY   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d Section of Hematology Oncology   (United States)

Author keywords

Chronic myelogenous leukemia; Focal segmental glomerulosclerosis; Hepatitis C; Interferon alpha; Nephrotic syndrome

Indexed keywords

ALPHA INTERFERON; ANTIDEPRESSANT AGENT; DIURETIC AGENT; FUROSEMIDE; HYDROXYUREA; IMATINIB; METOLAZONE; PAROXETINE; PREDNISONE;

ADULT; ARTICLE; CANCER IMMUNOTHERAPY; CASE REPORT; CHRONIC ACTIVE HEPATITIS; CHRONIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; DEPRESSION; EDEMA; FOCAL GLOMERULOSCLEROSIS; HEPATITIS C; HUMAN; INTERSTITIAL NEPHRITIS; KIDNEY BIOPSY; LEUKOCYTE COUNT; LIVER BIOPSY; MALE; NEPHROTIC SYNDROME; NEPHROTOXICITY; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS; BIOLOGICAL RESPONSE MODIFIERS; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LEUKEMIA, MYELOID, CHRONIC; MALE;

EID: 0037841391     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200306000-00011     Document Type: Article

References (39)

1. Sawyer CL. Chronic myeloid leukemia. N Engl J Med 1999;340: 1330-40.
2. Kantarjian HM, O'Brien S, Anderlini P, et al. Treatment of chronic myelogenous leukemia: current status and investigational options. Blood 1996;87:3069-81.
3. Alimena G, Morra E, Lazzarino M, et al. Interferon alpha-2b as therapy for Ph-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration. Blood 1988;72:642-7.
4. Ozer H, George SL, Schiffer CA, et al. Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic- phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583. Blood 1993;82:2975-84.
5. Mahon FX, Faberes C, Pueyo S, et al. Response at three months is a good predictive factor for newly diagnosed chronic myeloid leukemia patients treated by recombinant interferon-alpha. Blood 1998;92:4059-65.
6. Kantarjian H, Smith T, O'Brien S, et al. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon alpha therapy. The Leukemia Service. Ann Intern Med 1995;122:254-61.
7. Quesada JT, Talpaz M, Rios A, et al. Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol 1986;4:234-43.
8. Shah M, Jenis EH, Mookerjee BK, et al. Interferon-a-associated focal segmental glomerulosclerosis with massive proteinuria in patients with chronic myeloid leukemia following high dose chemotherapy. Cancer 1998;83:1938-46.
9. Johnson RJ, Gretch DR, Yamabe H, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993;328:465-70.
10. Altraif IH, Abdulla AS, al Sebayel MI, et al. Hepatitis C associated glomerulonephritis. Am J Nephrol 1995;15:407-10.
11. Coroneos E, Petrusevska G, Varghese F, et al. Focal segmental glomerulosclerosis with acute renal failure associated with alpha-interferon therapy. Am J Kidney Dis 1996;28:888-92.
12. Sacchi S, Kantarjian H, O'Brien S, et al. Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia. J Clin Oncol 1995;13:2401-7.
13. Jadoul M, Piessevaux H. Ferrant A, et al. Renal thrombotic microangiopathy in patients with chronic myelogenous leukemia treated with interferon-α2b. Nephrol Dial Transplant 1995;10: 111-3.
14. Schlaifer D, Dumazer P, Spenatto N, et al. Hemolytic-uremic syndrome in a patient with chronic myelogenous leukemia treated with interferon alpha [letter]. Am J Hematol 1994;47:254-5.
15. Lederer E, Truong L. Unusual glomerular lesion in a patient receiving long-term interferon alpha. Am J Kidney Dis 1992;20: 516-8.
16. 2a therapy for chronic myeloid leukemia [letter]. Am J Hematol 1995;49: 355-6.
17. Selby P, Kohn J, Raymond J, et al. Nephrotic syndrome during treatment with interferon. BMJ 1985;290:1180.
18. Fahal IH, Murry N, Chu P, et al. Acute renal failure during interferon treatment. BMJ 1993;306:973.
19. Sawamura M, Matsushima T, Tamura J, et al. Renal toxicity in long-term alpha-interferon treatment in a patient with myeloma [letter]. Am J Hematol 1992;41:146.
20. Noel C, Vrtovsnik F, Facon T, et al. Acute and definitive renal failure in progressive multiple myeloma treated with recombinant interferon alpha-2a: report of two patients [letter]. Am J Hematol 1992;41:298-9.
21. Cooper MR, Fefer A, Thompson J, et al. Alpha-2-interferon/ melphalan/prednisone in previously untreated patients with multiple myeloma: a phase I-II trial. Cancer Treat Rep 1986;70:473-6.
22. Averbuch SD, Austin HA III, Sherwin SA, et al. Acute interstitial nephritis with the nephrotic syndrome following recombinant leukocyte A interferon therapy for mycosis fungoides. N Engl J Med 1984;310:32-5.
23. Nair S, Ernstoff MS, Bahson RR, et al. Interferon- induced reversible acute renal failure with nephrotic syndrome. Urology 1992; 29:169-72.
24. Horowitz R, Glocklich D, Sablay L, et al. Inteferon-induced acute renal failure: a case report and literature review. Med Oncol 1995;12:55-7.
25. Gagoo ES, Luno E, Quinones L, et al. Chronic myelogenous leukemia and glomerulonephritis: report of a new case. Am J Med 1986;81:1121-22.
26. Sudholt BA, Heironimus JD. Chronic myelogenous leukemia with nephrotic syndrome. Arch Intern Med 1983;143:168-9.
27. Majdan M, Dmoszynska A, Wojtaszko M, et al. Chronic myelogenous leukaemia associated with rapidly progressive glomerulonephritis. Nephrol Dial Transplant 1994;9:562-3.
28. Bocci V, DeFrancesco P, Pacini A, et al. Renal metabolism of homologous serum interferon. Antiviral Res 1983;3:53-8.
29. Detwiler RK, Falk RJ, Hogan SL, et al. Collapsing glomerulopathy: a clinically and histologically distinct variant of focal segmental glomerulosclerosis. Kidney Int 1994;45:1416-24.
30. Valeri A, Barisoni L, Appel GB, et al. Idiopathic collapsing focal segmental glomerulosclerosis: a clinicopathologic study. Kidney Int 1996;50:1734-46.
31. Cattran DC, Rao P. Long-term outcome in children and adults with classic focal segmental glomerulosclerosis. Am J Kidney Dis 1998; 32:72-9.
32. Pei Y, Cattran D, Delmore T, et al. Evidence suggesting under-treatment in adults with idiopathic focal segmental glomerulosclerosis. Regional Glomerulonephritis Registry study. Am J Med 1987;82:938-44.
33. Matalon R, Katz L, Gallo G, et al. Glomerular sclerosis in adults with nephrotic syndrome. Ann Intern Med 1974;81:324-20.
34. Lim VS, Sibley R, Spargo B. Adult lipoid nephrosis: clinicopathological correlations. Ann Intern Med 1974;81:314-20.
35. Rydel JJ, Korbet SM, Borok RZ, et al. Focal segmental glomerular sclerosis in adults: presentation, course, and response to treatment. Am J Kidney Dis 1995;25:534-42.
36. Nagai R, Cattran DC, Pei Y. Steroid therapy and prognosis of focal segmental glomerulosclerosis in the elderly. Clin Nephrol 1994; 42:18-21.
37. Matalon A, Valeri A, Appel GB. Treatment of focal segmental glomerulosclerosis. Semin Nephrol 2000;20:309-17.
38. Korbet SM. Primary focal segmental glomerulosclerosis. J Am Soc Nephrol 1998;9:1333-40.
39. Meyrier A, Noel LH, Auriche P, et al. Long-term renal tolerance of cyclosporin A treatment in adult idiopathic nephrotic syndrome. Kidney Int 1994;45:1446-56.